Diagnosis | Location of BAL | Mean (SE) active TGF-β (fmol/106 AM) | Mean (SE) total TGF-β (fmol/106 AM) | Active TGF-β (%) | Isoforms of TGF-β (% of total) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
TGF-β1 | TGF-β2 | TGF-β3 | |||||||||
IPF2-150 | Upper lobes | 1.6 (0.6) | 1.7 (0.8) | 95.8 (1.5) | ND | ND | ND | ||||
IPF2-150 | Lower lobes | 4.1 (1.9) | 5.4 (2.4) | 73.3 (18.2) | 75 (2.2) | 10.2 (0.3) | 14.8 (0.8) | ||||
Control2-151 | Lower lobes | 0.0 | 0.7 (0.2) | 0.0 | 15 (2.2) | 29.5 (1.2) | 55.5 (0.9) |
IPF = idiopathic pulmonary fibrosis; BAL = bronchoalveolar lavage; ND = not done.
↵2-150 Each patient with IPF had a BAL of the upper and lower lobes (n=5).
↵2-151 Control patients are described in table 1 (n=5).
p⩽0.01 for active TGF-β, p⩽0.01 for % active TGF-β in CM, and p⩽0.01 for difference of all isoforms of TGF-β CM of lower lobe AM of patients with IPF v control samples. Difference between CM of upper lobe and lower lobe AMs from IPF patients did not reach statistical significance (Mann-Whitney test).